Compare
IDEAYA Biosciences, Inc. vs Puma Biotechnology, Inc. vs Anaptysbio, Inc vs Arcus Biosciences, Inc.
| Latest fiscal year | IDEAYA Biosciences, Inc. IDYA | Puma Biotechnology, Inc. PBYI | Anaptysbio, Inc ANAB | Arcus Biosciences, Inc. RCUS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $218.71M | $228.37M | $234.60M | $247.00M |
| Revenue growth (YoY) | n/m | -0.9% | +157.0% | -4.3% |
| Gross margin | n/a | 74.5% (computed) | n/a | n/a |
| Operating margin | -72.8% | 16.3% | 20.4% | -156.3% |
| Net margin | -52.0% | 13.6% | -5.6% | -142.9% |
| Net income | -$113.70M | $31.11M | -$13.23M | -$353.00M |
| EPS (Diluted) | -$1.28 | $0.61 | -$0.46 | -$3.29 |
| Operating cash flow | -$71.10M | $41.80M | $19.70M | -$482.00M |
| Free cash flow | -$73.47M | $41.73M | $19.61M | -$484.00M |
| Cash & equivalents | $112.83M | $29.64M | $238.20M | $222.00M |
| Total assets | $1.11B | $216.30M | $364.39M | $1.14B |
| Total liabilities | $86.39M | $85.96M | n/a | n/a |
| Shareholders' equity | $1.02B | $130.34M | $37.21M | $631.00M |
| Return on year-end equity | -11.1% | 23.9% | -35.6% | -55.9% |
| Shares outstanding | 87.80M | 50.41M | 28.02M | 125.30M |
Revenue, most recent five fiscal years
| Fiscal year | IDEAYA Biosciences, Inc. | Puma Biotechnology, Inc. | Anaptysbio, Inc | Arcus Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $218.71M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $234.60M Ended 2025-12-31 | $247.00M Ended 2025-12-31 |
| 1 year earlier | $7.00M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $91.28M Ended 2024-12-31 | $258.00M Ended 2024-12-31 |
| 2 years earlier | $23.39M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $17.16M Ended 2023-12-31 | $117.00M Ended 2023-12-31 |
| 3 years earlier | $50.93M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $10.29M Ended 2022-12-31 | $112.00M Ended 2022-12-31 |
| 4 years earlier | $27.94M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $63.17M Ended 2021-12-31 | $383.00M Ended 2021-12-31 |